DE69902758T2 - 2-(purin-9-yl)-tetrahydrofuran-3,4-diol-derivative - Google Patents

2-(purin-9-yl)-tetrahydrofuran-3,4-diol-derivative

Info

Publication number
DE69902758T2
DE69902758T2 DE69902758T DE69902758T DE69902758T2 DE 69902758 T2 DE69902758 T2 DE 69902758T2 DE 69902758 T DE69902758 T DE 69902758T DE 69902758 T DE69902758 T DE 69902758T DE 69902758 T2 DE69902758 T2 DE 69902758T2
Authority
DE
Germany
Prior art keywords
purin
tetrahydro
diol
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69902758T
Other languages
English (en)
Other versions
DE69902758D1 (de
Inventor
Chuen Chan
Caroline Mary Cook
Brian Cox
Richard Peter C Cousins
Hazel Joan Dyke
Frank Ellis
Joanna V Geden
Stephen Swanson
David Bays
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26313119&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69902758(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9803169.3A external-priority patent/GB9803169D0/en
Priority claimed from GBGB9813533.8A external-priority patent/GB9813533D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of DE69902758D1 publication Critical patent/DE69902758D1/de
Application granted granted Critical
Publication of DE69902758T2 publication Critical patent/DE69902758T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69902758T 1998-02-14 1999-02-12 2-(purin-9-yl)-tetrahydrofuran-3,4-diol-derivative Expired - Fee Related DE69902758T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9803169.3A GB9803169D0 (en) 1998-02-14 1998-02-14 Chemical compounds
GBGB9813533.8A GB9813533D0 (en) 1998-06-23 1998-06-23 Chemical compounds
PCT/EP1999/000915 WO1999041267A1 (en) 1998-02-14 1999-02-12 2-(purin-9-yl) -tetrahydrofuran-3, 4-diol derivatives

Publications (2)

Publication Number Publication Date
DE69902758D1 DE69902758D1 (de) 2002-10-10
DE69902758T2 true DE69902758T2 (de) 2003-05-15

Family

ID=26313119

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69902758T Expired - Fee Related DE69902758T2 (de) 1998-02-14 1999-02-12 2-(purin-9-yl)-tetrahydrofuran-3,4-diol-derivative

Country Status (32)

Country Link
US (1) US6610665B1 (de)
EP (1) EP1056759B1 (de)
JP (1) JP2002503669A (de)
KR (1) KR20010082512A (de)
AP (1) AP2000001881A0 (de)
AR (1) AR017457A1 (de)
AT (1) ATE223429T1 (de)
AU (1) AU757156B2 (de)
BR (1) BR9907886A (de)
CA (1) CA2319009A1 (de)
CO (1) CO4990969A1 (de)
DE (1) DE69902758T2 (de)
DK (1) DK1056759T3 (de)
EA (1) EA200000759A1 (de)
EE (1) EE200000358A (de)
ES (1) ES2183516T3 (de)
HK (1) HK1032062A1 (de)
HR (1) HRP20000538A2 (de)
HU (1) HUP0100702A3 (de)
IL (1) IL137402A0 (de)
IS (1) IS5576A (de)
MA (1) MA27121A1 (de)
NO (1) NO20004045D0 (de)
NZ (1) NZ505812A (de)
PE (1) PE20000270A1 (de)
PL (1) PL342396A1 (de)
PT (1) PT1056759E (de)
SK (1) SK12002000A3 (de)
SV (1) SV1999000016A (de)
TR (1) TR200002355T2 (de)
WO (1) WO1999041267A1 (de)
YU (1) YU50800A (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514949B1 (en) 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
YU44900A (sh) * 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
CO4990969A1 (es) * 1998-02-14 2000-12-26 Glaxo Group Ltd Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol
GB9813565D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
SK19542000A3 (sk) * 1998-06-23 2001-09-11 Glaxo Group Limited 2-(purin-9-yl)-tetrahydrofurn-3,4-diolov derivty, spsob ich vroby, farmaceutick prostriedok s ich obsahom, ich pouitie a medziprodukty
GB9813554D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
US7427606B2 (en) 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US7214665B2 (en) 2001-10-01 2007-05-08 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof
GB9930075D0 (en) * 1999-12-20 2000-02-09 Glaxo Group Ltd Medicaments
US7638496B2 (en) 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
GB0022695D0 (en) 2000-09-15 2000-11-01 Pfizer Ltd Purine Derivatives
GB0115178D0 (en) * 2001-06-20 2001-08-15 Glaxo Group Ltd Compounds
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
US6930093B2 (en) * 2003-07-10 2005-08-16 Valeant Research & Development Use of ribofuranose derivatives against inflammatory bowel diseases
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
TWI346109B (en) 2004-04-30 2011-08-01 Otsuka Pharma Co Ltd 4-amino-5-cyanopyrimidine derivatives
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
EP1778712B1 (de) 2004-08-02 2013-01-30 University Of Virginia Patent Foundation 2-propynyl-adenosin-analoga mit modifizierten 5'-ribosegruppen mit a2a-agonistenaktivität
WO2006028618A1 (en) 2004-08-02 2006-03-16 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
US7442687B2 (en) 2004-08-02 2008-10-28 The University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
CA2625664C (en) 2005-10-21 2016-01-05 Novartis Ag Human antibodies against il13 and therapeutic uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
CA2664378A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as pi3k lipid kinase inhibitors
CA2667962A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
AU2009203693B2 (en) 2008-01-11 2012-06-07 Novartis Ag Pyrimidines as kinase inhibitors
TW201031406A (en) 2009-01-29 2010-09-01 Novartis Ag Substituted benzimidazoles for the treatment of astrocytomas
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
CA2770873A1 (en) 2009-08-12 2011-02-17 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
IN2012DN01961A (de) 2009-08-17 2015-08-21 Intellikine Llc
EP2467383A1 (de) 2009-08-20 2012-06-27 Novartis AG Heterocyclische oximverbindungen
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
EP2673277A1 (de) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4] triazolo [4, 3]pyridazinverbindungen als inhibitoren dec-met-tyrosinkinase
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
SG192795A1 (en) 2011-02-25 2013-09-30 Irm Llc Compounds and compositions as trk inhibitors
ES2691650T3 (es) 2011-09-15 2018-11-28 Novartis Ag 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como inhibidores de tirosina quinasa c-Met
US9174994B2 (en) 2011-11-23 2015-11-03 Intellikine, Llc Enhanced treatment regimens using mTor inhibitors
RU2660354C2 (ru) 2012-04-03 2018-07-05 Новартис Аг Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
CN107207510B (zh) 2014-07-31 2019-11-29 诺华股份有限公司 联合疗法
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9414193D0 (en) 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
TW528755B (en) * 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
CO4990969A1 (es) * 1998-02-14 2000-12-26 Glaxo Group Ltd Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol
SK19542000A3 (sk) * 1998-06-23 2001-09-11 Glaxo Group Limited 2-(purin-9-yl)-tetrahydrofurn-3,4-diolov derivty, spsob ich vroby, farmaceutick prostriedok s ich obsahom, ich pouitie a medziprodukty

Also Published As

Publication number Publication date
MA27121A1 (fr) 2005-01-03
HUP0100702A3 (en) 2003-01-28
TR200002355T2 (tr) 2000-11-21
HRP20000538A2 (en) 2000-12-31
AU757156B2 (en) 2003-02-06
SK12002000A3 (sk) 2001-07-10
NO20004045L (no) 2000-08-11
JP2002503669A (ja) 2002-02-05
CA2319009A1 (en) 1999-08-19
EA200000759A1 (ru) 2001-04-23
PE20000270A1 (es) 2000-05-20
CO4990969A1 (es) 2000-12-26
NO20004045D0 (no) 2000-08-11
NZ505812A (en) 2002-03-01
DE69902758D1 (de) 2002-10-10
IL137402A0 (en) 2001-07-24
AU2623599A (en) 1999-08-30
BR9907886A (pt) 2000-10-17
IS5576A (is) 2000-07-25
DK1056759T3 (da) 2003-01-06
US6610665B1 (en) 2003-08-26
WO1999041267A1 (en) 1999-08-19
PT1056759E (pt) 2003-01-31
AR017457A1 (es) 2001-09-05
AP2000001881A0 (en) 2000-09-30
ES2183516T3 (es) 2003-03-16
HUP0100702A2 (hu) 2002-01-28
YU50800A (sh) 2003-04-30
HK1032062A1 (en) 2001-07-06
SV1999000016A (es) 1999-10-27
KR20010082512A (ko) 2001-08-30
EP1056759A1 (de) 2000-12-06
EP1056759B1 (de) 2002-09-04
EE200000358A (et) 2001-10-15
ATE223429T1 (de) 2002-09-15
PL342396A1 (en) 2001-06-04

Similar Documents

Publication Publication Date Title
DE69902758D1 (de) 2-(purin-9-yl)-tetrahydrofuran-3,4-diol-derivative
DK1051425T3 (da) 2-(Purin-9-yl)-tetrahydrofuran-3,4-diolderivater
IS5779A (is) 2-(púrín-9-ýl)-tetrahýdrófúran-3,4-díól afleiður
IS5774A (is) 2-(púrín-9-ýl)-tetrahýdrófúran-3,4-díól afleiður
DK0948509T3 (da) 2-(Purin-9-yl)-tetrahydrofuran-3,4-diolderivater
CU23049A3 (es) Dihidropirimidinas.
IT1302016B1 (it) Fluoroelastomeri.
FI980098A0 (fi) Anordning i torkpartiet i en bestrykningsanordning, pappersmaskin eller motsvarande
NO982498D0 (no) Fleksibel, fjµrende svepe
FI980699A0 (fi) Fastsaettningsdon foer bordsskiva, i synnerhet foer hjaelpbord eller motsvarande
ZA99689B (en) 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives.
ZA991154B (en) 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives.
ES1040589Y (es) Expositor-dispensador.
ES1040633Y (es) Escalifono.
ES1039730Y (es) Rodapie.
ES1040343Y (es) Carrito portafregona.
ES1040731Y (es) Gafa.
ES1042117Y (es) Mesa-sombrilla.
ES1039413Y (es) Nueva ficha-deportista.
ITNA980067A1 (it) Bloccatappo.
ITBO980260A1 (it) Riavvolgicarta.
ES1040479Y (es) Multihorno para paellas.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee